

#### STATISTICAL ANALYSIS PLAN

**Study Title:** A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long

Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with

Multidrug Resistance

Name of Test Drug: Lenacapavir (LEN; GS-6207)

Study Number: GS-US-200-4625

**Protocol Version (Date):** Amendment 2 (01 September 2020)

**Analysis Type:** Primary (Week 26 Interim) Analysis

**Analysis Plan Version:** Version 1.0

**Analysis Plan Date:** 19 April 2021

Analysis Plan Author(s): PPD

CONFIDENTIAL AND PROPRIETARY INFORMATION

# **TABLE OF CONTENTS**

ΤA	BLE O	F CONTENTS					
LIS	T OF I	N-TEXT TABLES	4				
		BBREVIATIONS					
1.	INTR	ODUCTION					
	1.1.	Study Objectives					
	1.2.	Study Design					
	1.3.	Sample Size and Power					
2.	TYPE	E OF PLANNED ANALYSIS	10				
	2.1.	Interim Analyses	10				
		2.1.1. Data Monitoring Committee Analysis/Primary Efficacy Analysis					
		2.1.2. Primary (Week 26) Analysis					
		2.1.3. Week 52 Analysis					
	2.2.	Final Analysis					
3.	GENI	ERAL CONSIDERATIONS FOR DATA ANALYSES	12				
	3.1.	Analysis Sets	12				
		3.1.1. All Enrolled Analysis Set					
		3.1.2. Full Analysis Set.					
		3.1.3. Per-Protocol Analysis Set					
		3.1.4. Safety Analysis Set	13				
	3.2.	CCI Subject Grouping	1.				
	3.2. 3.3.	Strata and Covariates					
	3.4.	Examination of Subject Subgroups					
	5.1.	3.4.1. Subject Subgroups for Efficacy Analyses					
		3.4.2. Subject Subgroups for Safety Analyses					
	3.5.	Multiple Comparisons	15				
	3.6.	Missing Data and Outliers					
		3.6.1. Missing Data					
	3.7.	3.6.2. Outliers					
	3.7.	Analysis Visit Windows					
	5.0.	3.8.1. Definition of Key Dates and Study Day.					
		3.8.2. Analysis Visit Windows					
		3.8.3. Selection of Data in the Event of Multiple Records in an Analysis Visit	10				
4	CLIDI	Window					
4.	SUBJ	SUBJECT DISPOSITION					
	4.1. Subject Enrollment and Disposition						
	4.2. Study Drug Administration and Adherence						
	4.3. 4.4.	Study Duration					
_							
5.	BASI	ELINE CHARACTERISTICS	24				
	5.1.	Demographics and Baseline Characteristics					
	5.2.	Other Baseline Characteristics					
	5.3.	Medical History	26				
6	EFFI	CACY ANALYSES	25				

	6.1.	Primary	Efficacy End	lpoint	27
	6.2.	Seconda	ry Efficacy E	Endpoints	27
		6.2.1.	US FDA-	defined Snapshot Algorithm	28
	6.3.	Other E	fficacy Endpo	oints	29
		6.3.1.	Definition	of Other Efficacy Endpoints	29
		6.3.2.	Analysis o	of Other Efficacy Endpoints	29
	6.4.	Subgrou	p Analysis	· · · · · · · · · · · · · · · · · · ·	31
	6.5.	Changes	from Protoco	ol-Specified Efficacy Analyses	31
7.	SAFE	TY ANAI	YSES		32
	7.1.	Adverse	Events and I	Deaths	32
		7.1.1.	Adverse E	Event Dictionary	32
		7.1.2.	Adverse E	Event Severity	32
		7.1.3.		nip of Adverse Events to Study Drug	
		7.1.4.		dverse Events	
		7.1.5.		t-Emergent Adverse Events	
			7.1.5.1.	Definition of Treatment-Emergent Adverse Events	
			7.1.5.2.	Incomplete Dates	
		7.1.6.	The second secon	es of Adverse Events and Deaths	
		940704FR	7.1.6.1.	Summaries of AE Incidence in Combined Severity Grade	
			a describer	Subsets	33
		7.1.7.	Additional	1 Analysis of Adverse Events	
		AND	7.1.7.1.	Study Drug Related Injection Site Reactions	
	7.2.	Laborate		ns	
		7.2.1.		es of Numeric Laboratory Results	
		7.2.2.		aboratory Values	
		7.2.2.	7.2.2.1.		
			7.2.2.2.	Summaries of Laboratory Abnormalities	
	7.3.	Rody W		al Signs	
	7.4.			ations and Concomitant Medications	
	100	7.4.1.		riral Medications	
		/1.	7.4.1.1.	Prior Antiretroviral Medications.	
			7.4.1.2.		
			7.4.1.3.	Optimized Background Regimen at Baseline	
		7.4.2.	Andreas manager	ant Medications	
	7.5.	and the second second		esults	
	1.5.	7.5.1.		or Electrocardiogram Assessment	
	7.6.	100000000000000000000000000000000000000	The second secon	다는 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은	
	7.7.			es	
	7.8.	Changes	Hom Protoco	ol-Specified Safety Analyses	40
-0)					
		4			
9.	REFE	RENCES	8		43
10.					
11.	SAP I	REVISION	Ī		45
12	APPE	NDICES			46

# LIST OF IN-TEXT TABLES

Table 3-1.	Definitions of First Dose Date and Last Dose Date for Each Analysis	17
Table 3-2.	Analysis Windows for All LEN Analysis	18

#### LIST OF ABBREVIATIONS

AE adverse event ARV antiretroviral

BLQ below the limit of quantitation

BMI body mass index CI confidence interval

CMH Cochran-Mantel-Haenszel

COBI cobicistat

CSR clinical study report
CV coefficient of variation
DAIDS Division of AIDS

DMC data monitoring committee

ECG electrocardiogram

eCRF electronic case report form

FAS Full Analysis Set

FDA Food and Drug Administration
GSS genotypic sensitivity score

HLT high-level term ID identification

INSTI integrase strand-transfer inhibitor

ISR injection site reaction
LEN lenacapavir; GS-6207
LOQ limit of quantitation
M = E missing = excluded
M = F missing = failure
MDR multidrug resistance

MedDRA Medical Dictionary for Regulatory Activities

NNRTI non-nucleoside reverse transcriptase inhibitors

NRTI nucleoside reverse transcriptase inhibitors

OBR optimized background regimen
OSS overall susceptibility score

PI protease inhibitor
PK pharmacokinetics
PWH people with HIV
PP per protocol

PSS phenotypic sensitivity score

PT preferred term RTV ritonavir

Q1, Q3 first quartile, third quartile

SAE	serious adverse event
SAP	statistical analysis plan
SC	subcutaneous
SD	standard deviation
SE	standard error
SOC	system organ class
TEAE	treatment-emergent adverse event
TFLs	tables, figures, and listings
US	United States

WHO

World Health Organization

#### 1. INTRODUCTION

This statistical analysis plan (SAP) describes the statistical analysis methods and data presentations to be used in tables, figures, and listings (TFLs) of the Week 26 analysis for Study GS-US-200-4625. The Week 26 analysis will be performed when all Cohort 1 subjects have completed Week 26 assessment or prematurely discontinued the study drug. The purpose of this interim analysis is to support the lenacapavir (LEN; GS-6207) regulatory filing for the indication in the heavily treatment experienced people with HIV (PWH).

This SAP is based on the study protocol amendment 2 dated 01 September 2020 and the electronic case report form (eCRF). The SAP will be finalized prior to data finalization for the Week 26 analysis. Any changes made after the finalization of the SAP will be documented in the clinical study report (CSR).

## 1.1. Study Objectives

The primary objective of this study is as follows:

 To evaluate the antiviral activity of LEN administered as an add-on to a failing regimen (functional monotherapy) for PWH with multidrug resistance (MDR) as determined by the proportion of subjects achieving at least 0.5 log<sub>10</sub> reduction from baseline in HIV-1 RNA at the end of the Functional Monotherapy Period

The secondary objective of this study is as follows:

 To evaluate the safety and efficacy of LEN in combination with an optimized background regimen (OBR) at Weeks 26 and 52



## 1.2. Study Design

This is a Phase 2/3 global multicenter study of LEN together with an OBR in PWH with MDR infection. Subjects who complete a Screening visit will return to the clinic between 14 and 30 days after the Screening visit, for a Cohort Selection visit. HIV-1 RNA results from the Cohort Selection visit will be used to determine whether eligible subjects will participate in Cohort 1 or Cohort 2.

## **Cohort 1 (n=36)**

### **Functional Monotherapy Period**

Eligible subjects with a  $< 0.5 \log_{10}$  HIV-1 RNA decline compared to the Screening visit and HIV-1 RNA  $\geq 400$  copies/mL at the Cohort Selection visit will be randomized in a 2:1 ratio to receive either oral LEN or placebo to match LEN for 14 days. Treatment assignment will be blinded to the sponsor, subjects, investigators and study staff at the site. Functional monotherapy will be assessed while subjects continue their failing regimen. After each subject completes the Functional Monotherapy Period, their treatment assignment will be unblinded.

#### **Maintenance Period**

Subjects who were randomized to receive oral LEN will receive subcutaneous (SC) LEN and initiate their OBR on Day 1 SC (14 days after the first dose of oral LEN) (Cohort 1A).

Subjects who were randomized to receive placebo will receive oral LEN and initiate their OBR on Day 15 (Cohort 1B). They will receive SC LEN at Day 1 SC (14 days after the first dose of oral LEN) while continuing their OBR.

After the Day 1 SC visit, all Cohort 1 subjects will continue with study visits and receive their subsequent SC LEN injection at the Week 26 visit. At the Week 52 visit, subjects will be given an option to receive SC LEN injection and continue on the study to receive SC LEN injections every 6 months (26 weeks).

#### **Cohort 2 (n=64)**

#### Oral Lead-in Period

Subjects will be enrolled into Cohort 2 if Cohort 1 is fully enrolled or if they do not meet the criteria for randomization in Cohort 1 (ie, they had  $\geq 0.5 \log_{10}$  HIV-1 RNA decline compared to the Screening visit and/or HIV-1 RNA < 400 copies/mL at the Cohort Selection visit). All Cohort 2 subjects will receive oral LEN for 14 days starting at Day 1. Subjects will initiate an OBR on Day 1.

### **Maintenance Period**

At Day 1 SC (14 days after the first dose of oral LEN), subjects will receive SC LEN and will continue their OBR. After the Day 1 SC visit, subjects will continue with study visits and receive their subsequent SC LEN injection at the Week 26 visit. At the Week 52 visit, subjects will be given an option to receive SC LEN injection and continue the study to receive SC LEN injections every 6 months (26 weeks).

For both Cohorts 1 and 2, data collected through Week 52 (52 weeks from the first dose of SC LEN) refer to as the "Main Phase" of the study. Data collected post Week 52 refer to as the "Extension Phase" of the study.

Schedule of Assessments is provided in Section 12 (Appendix 1).

## 1.3. Sample Size and Power

A total of 36 subjects in Cohort 1 will provide at least 90% power to detect a 60% difference in the proportion of subjects achieving a  $\geq 0.5 \log_{10}$  reduction from baseline at Day 15 of the Functional Monotherapy Period between the treatment groups (LEN in Cohort 1A and placebo in Cohort 1B).

In this sample size and power computation, it is assumed that 70% and 10% of subjects achieve a  $\geq 0.5 \log_{10}$  reduction from baseline in HIV-1 RNA in the LEN group (Cohort 1A) and the placebo group (Cohort 1B), respectively (based on data from Trogarzo Phase 3 TMB-301 study {Emu 2018}), and the Fisher exact test is conducted at 2-sided significant level of 0.05.

A total sample size of 36 subjects from Cohorts 1A and 1B will provide reasonable assessment of safety through at least 26 weeks of LEN treatment in heavily treatment experienced subjects.

## 2. TYPE OF PLANNED ANALYSIS

## 2.1. Interim Analyses

## 2.1.1. Data Monitoring Committee Analysis/Primary Efficacy Analysis

One external multidisciplinary Data Monitoring Committee (DMC) analysis is planned to review the progress of the study and to perform interim reviews of the efficacy and safety data. The DMC will convene after all subjects in Cohort 1 have completed or discontinued the study drug in the Functional Monotherapy Period. Treatment assignment will be unblinded for the DMC analysis.

No formal stopping rules will be used by the DMC for safety outcomes. Rather, a clinical assessment will be made to determine if the nature, frequency, and severity of adverse events (AEs) associated with a study regimen warrant the early termination of the study in the best interest of the subjects.

Gilead does not have a prior intent to ask the DMC to consider early termination of the study even if there is an early evidence of favorable efficacy. However, Gilead will stop further enrollment if 50% or more of the subjects in the LEN group fail in Cohort 1 to achieve at least 0.5 log<sub>10</sub> reduction from baseline in HIV-1 RNA at the end of the Functional Monotherapy Period. The decision whether to continue with the study and the development of LEN will be based on the magnitude of the HIV-1 RNA decline at the end of the Functional Monotherapy Period.

The DMC's role and responsibilities and the scope of analysis to be provided to the DMC are defined in a mutually agreed upon charter, which defines the DMC membership, meeting logistics, and meeting frequency, and in the DMC SAP.

## 2.1.2. Primary (Week 26) Analysis

Analysis at Week 26 will be conducted after all subjects in Cohort 1 have completed the Week 26 visit (ie, 26 weeks after the first dose of SC LEN) or have prematurely discontinued the study drug, outstanding data queries have been resolved or adjudicated as unresolvable, and the data have been cleaned and finalized for the analysis. The data from this analysis will be used to support the LEN regulatory filing for the indication in the heavily treatment experienced PWH.

This SAP describes the analysis plan for the Week 26 analysis.

# 2.1.3. Week 52 Analysis

Analysis at Week 52 will be conducted after all subjects in Cohort 1 have completed the Week 52 visit (ie, 52 weeks after the first dose of SC LEN) and/or after all subjects in Cohort 2 have completed the Week 26 visit (ie, 26 weeks after the first dose of SC LEN) or have prematurely discontinued the study drug, outstanding data queries have been resolved or adjudicated as unresolvable, and the data have been cleaned and finalized for the analysis.

## 2.2. Final Analysis

After all subjects have completed the study, outstanding data queries have been resolved or adjudicated as unresolvable, and the data have been cleaned and finalized, final analysis of the data will be performed.

## 3. GENERAL CONSIDERATIONS FOR DATA ANALYSES

The following two sets of analyses are defined for this study. Data included in each analysis are defined as follows:

## **Functional Monotherapy Period Analysis**

Functional Monotherapy Period analysis only applies to Cohort 1 and includes data collected from subjects randomized in the Functional Monotherapy Period. All data collected from first dose of blinded study drug up to the first dose date of the open-label study drug, defined as the earliest date of either SC LEN or open-label oral LEN, will be included in this analysis except for data on AEs and death. For AEs and death, only data collected prior to the first dose date of the open-label study drug will be included.

Data included in this analysis will be used to assess the primary efficacy endpoint and safety data collected during the blinded phase of the study. Results will be summarized by treatment group (LEN vs. Placebo).

## **All LEN Analysis**

All LEN analysis include data collected from subjects who receive at least one dose of LEN (ie, oral LEN [blinded or open-label] or SC LEN). Data collected on and after the first dose of LEN are included in this analysis. Data included in this analysis will be used to assess efficacy, safety, CCI.

Results will be summarized by cohort and total, unless specified otherwise.

#### **General Analysis Approaches**

Analysis results will be presented using descriptive statistics. For categorical variables, the number and percentage of subjects in each category will be presented; for continuous variables, the number of subjects (n), mean, standard deviation (SD) or standard error (SE), median, first quartile (Q1), third quartile (Q3), minimum, and maximum will be presented.

By-subject listings will be presented for all subjects in the All Enrolled Analysis Set and sorted by cohort, subject identification (ID) number, visit date, and time (if applicable). Data collected on log forms, such as AEs, will be presented in chronological order within the subject. The treatment group to which subjects were enrolled will be used in the listings. Age, sex at birth, race, and ethnicity will be included in the listings, as space permits.

#### 3.1. Analysis Sets

Analysis sets define the subjects to be included in an analysis. Analysis sets and their definitions are provided in this section. The analysis set will be identified and included as a subtitle of each TFLs.

For each analysis set, the number and percentage of subjects will be summarized by cohort based on the All Enrolled Analysis Set.

A listing of reasons for exclusion from analysis sets will be provided by subject.

## 3.1.1. All Enrolled Analysis Set

All Enrolled Analysis Set includes all subjects who were randomized into Cohort 1 or enrolled into Cohort 2. This is the primary analysis set for by-subject listings.

# 3.1.2. Full Analysis Set

The Full Analysis Set (FAS) is the primary analysis set for efficacy analyses. Two FASs are defined for this study:

- FAS for the Functional Monotherapy Period analysis: this analysis set includes all subjects who are randomized in the Functional Monotherapy Period and receive at least one dose of blinded study drug. This is the primary analysis set for the primary efficacy endpoint.
- FAS for the All LEN analysis: this analysis set includes all subjects who are enrolled into the study and receive at least one dose of SC LEN. This is the primary analysis set for the secondary efficacy endpoint and other efficacy endpoints.

## 3.1.3. Per-Protocol Analysis Set

A Per-Protocol (PP) Analysis Set is defined for the primary efficacy analysis. This analysis set includes all subjects in the FAS for the Functional Monotherapy Period analysis excluding subjects meeting any of the following criteria:

- Received partial or missed doses on Day 1, Day 2, or Day 8
- Did not have any postbaseline HIV-1 RNA collected during the Functional Monotherapy Period
- Added a new antiretroviral (ARV) during the Functional Monotherapy Period
- Did not meet the criteria for randomization in Cohort 1, that is, subjects had ≥ 0.5 log<sub>10</sub>
  HIV-1 RNA decline compared to the Screening visit and/or HIV-1 RNA < 400 copies/mL at
  the Cohort Selection visit</li>

## 3.1.4. Safety Analysis Set

The Safety Analysis Set includes all subjects who are enrolled and receive at least one dose of study drug. This is the primary analysis set for safety analyses. This analysis set will be used to describe baseline information as well as safety summary for the Functional Monotherapy Period analysis and All LEN analysis.

# 3.2. Subject Grouping

For analyses based on the FAS, subjects will be grouped according to the treatment to which they were enrolled. For analyses based on the PP, Safety, CCI subjects will be grouped according to the actual treatment received.

#### 3.3. Strata and Covariates

This study does not use a stratified randomization schedule when enrolling subjects. No covariates will be included in efficacy analyses.

# 3.4. Examination of Subject Subgroups

# 3.4.1. Subject Subgroups for Efficacy Analyses

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 26 as determined by the United States (US) Food and Drug Administration (FDA)-defined snapshot algorithm {U. S. Department of Health and Human Services 2015} will be analyzed for the following subject subgroups based on FAS for the All LEN analysis:

- Age (years): (a) < 50 and (b)  $\ge 50$
- Sex: (a) male and (b) female
- Race: (a) black and (b) nonblack
- Region: (a) US and (b) Ex-US
- Baseline CD4 cell count categories ( $/\mu$ L): (a) < 200 and (b) > 200
- Baseline viral load categories (copies/mL): (a) ≤ 100,000 and (b) > 100,000
- Baseline INSTI resistance categories: (a) with INSTI resistance and (b) without INSTI resistance
- Genotypic sensitivity score (GSS) based on baseline OBR: eg, 0, 1, 2, etc.
- Phenotypic sensitivity score (PSS) based on baseline OBR: eg, 0, 1, 2, etc.
- Overall susceptibility score (OSS) based on baseline OBR: eg, 0, 1, 2, etc.

# 3.4.2. Subject Subgroups for Safety Analyses

Incidence of all treatment-emergent AEs (TEAEs) will be analyzed for the following subject subgroups using the Safety Analysis Set for the All LEN analysis:

- Age (years): (a)  $\leq 50$  and (b)  $\geq 50$
- Sex: (a) male and (b) female
- Race: (a) black and (b) nonblack
- Region: (a) US and (b) Ex-US

## 3.5. Multiple Comparisons

The primary efficacy endpoint will be evaluated at the time when all subjects in Cohort 1 have completed the Functional Monotherapy Period or discontinued from the study drug. There will be no interim analyses before the analysis of the primary efficacy endpoint; therefore, no alpha level adjustment will be applied to the primary efficacy endpoint.

## 3.6. Missing Data and Outliers

# 3.6.1. Missing Data

In general, missing data will not be imputed unless methods for handling missing data are specified. Exceptions are presented in this document.

For missing last study date, imputation rules are described in Section 4.3. The handling of missing or incomplete dates for AE onset is described in Section 7.1.5.2, and for antiretroviral medications and concomitant medications in Section 7.4.

## **3.6.2. Outliers**

Outliers will be identified during the data management and data analysis process, but no sensitivity analyses will be conducted. All data will be included in the data analysis.

## 3.7. Data Handling Conventions and Transformations

Only year of birth is collected in this study. The following conventions will be used for the imputation of full date of birth:

- If year of birth is collected, "01 July" will be imputed as the day and month of birth
- If year of birth is missing, date of birth will not be imputed

In general, age collected at baseline (in years) will be used for analyses and presented in listings. If age at baseline is not available for a subject, age derived based on date of birth and the baseline visit date will be used instead. If an enrolled subject was not dosed with any study drug, the randomization/enrollment date will be used instead of the baseline visit date. For screen failures, the date the first informed consent was signed will be used for the age derivation. Age required for longitudinal and temporal calculations and analyses (eg, estimates of creatinine clearance) will be based on age derived from date of birth and the date of the measurement or event, unless otherwise specified.

Non-PK data that are continuous in nature but are less than the lower limit of quantitation (LOQ) or above the upper LOQ will be imputed as follows:

- A value that is 1 unit less than the LOQ will be used to calculate descriptive statistics if the datum is reported in the form of "< x" (where x is considered the LOQ). For example, if the values are reported as < 50 and < 5.0, values of 49 and 4.9, respectively, will be used to calculate summary statistics. An exception to this rule is any value reported as < 1 or < 0.1, etc. For values reported as < 1 or < 0.1, a value of 0.9 or 0.09, respectively, will be used to calculate summary statistics.
- A value that is 1 unit above the LOQ will be used to calculate descriptive statistics if the
  datum is reported in the form of "> x" (where x is considered the LOQ). Values with decimal
  points will follow the same logic as above.
- The LOQ will be used to calculate descriptive statistics if the datum is reported in the form of
  "≤x" or "≥x" (where x is considered the LOQ).

Logarithmic (base 10) transformations will be applied to HIV-1 RNA data for efficacy analysis. HIV-1 RNA results of 'No HIV-1 RNA detected' and "<20 cp/mL HIV-1 RNA Detected" will be imputed as 19 copies/mL for analysis purposes.





## 3.8. Analysis Visit Windows

# 3.8.1. Definition of Key Dates and Study Day

Definitions of the first dose date and the last dose date for each analysis are provided in Table 3-1.

Table 3-1. Definitions of First Dose Date and Last Dose Date for Each Analysis

Analysis	First Dose Date	Last Dose Date	
Functional Monotherapy Period Analysis	First dose date of blinded study drug (LEN or Placebo)	Last dose date of blinded study drug (LEN or Placebo) <sup>a</sup>	
All LEN Analysis	The earliest dose date of either blinded or open-label oral LEN	The latest dose date of either blinded or open-label oral LEN or SC LEN <sup>b</sup>	

a This date is defined for subjects who receive the open-label LEN (ie, completion of the Functional Monotherapy Period) or who do not receive the open-label LEN with study drug completion eCRF for the main phase marked as early termination (ie, discontinuation during the Functional Monotherapy Period).

Last Dose Date for the study is defined for subjects who prematurely discontinue study drug in any phase of the study or who complete study drug in the main phase and do not continue into the extension phase of the study as the latest dose date of any study drug including blinded study drug, open-label oral LEN, and SC LEN.

**Last Study Date** is defined as the latest date of clinic visits and/or laboratory visits, and/or AE onset and end dates, including the 30, 90, and 180-day follow-up visit dates for subjects who prematurely discontinue study or for subjects who complete the main phase of the study and decide not to continue into the extension phase of the study.

**Study Day** will be calculated from the first dose date of study drug and derived as follows:

- For postdose study days: Assessment Date First Dose Date + 1
- For study days prior to the first dose: Assessment Date First Dose Date

## 3.8.2. Analysis Visit Windows

Analysis visit windows are not defined for the Functional Monotherapy Period analysis due to short duration of follow-up. The nominal visit as recorded on the eCRF will be used when data are summarized by visit.

b This date is defined for subjects who prematurely discontinue study drug in any phase (ie, main phase or extension phase) of the study or who complete study drug in the main phase and do not continue into the extension phase of the study

For the All LEN analysis, subject's visits might not occur on protocol-specified visits. Therefore, for the purpose of analysis, observations will be assigned to analysis windows (see Table 3-2).

Table 3-2. Analysis Windows for All LEN Analysis

		Analysis Window Study Day Range		
Analysis Visit	Nominal Study Day	HIV-1 RNA and Vital Signs	Hematology, (Urine) Chemistry, Urinalysis, CD4 Cell Count, and CD4%	
Baseline		≤ First Dose Date, if time not available ≤ First Dose Date/Time, if time available	≤ First Dose Date, if time not available ≤ First Dose Date/Time, if time available	
Day 1 (Postdose) <sup>a</sup>	1	> First Dose Date/Time, 1	> First Dose Date/Time, 1	
Day 2	2	2, 5	NP	
Day 8	8	6, 11	2, 11	
Day 1 SC	15	12, 29	12, 29	
Week 4	43	30, 64	30, 64	
Week 10	85	65, 106	65, 106	
Week 16	127	107, 148	107, 148	
Week 22	169	149, 183	149, 183	
Week 26	197	184, 232	184, 232	
Week 36	267	233, 323	233, 323	
Week 52	379	324, 414	324, 414	
Week 62	449	415, 505	415, 505	
Week 78	561	506, 596	506, 596	

NP = Not planned by the protocol

# 3.8.3. Selection of Data in the Event of Multiple Records in an Analysis Visit Window

Depending on the statistical analysis method, single values may be required for each analysis window. For example, change from baseline by visit usually requires a single value, whereas a time-to-event analysis would not require 1 value per analysis window.

Day 1 postdose will be used to label the records collected on Day 1 with collection time after the Day 1 dosing time. The Day 1 postdose will be used in listings to identify such records. Day 1 postdose visit will not be included in by-visit table summary

If multiple valid, nonmissing measurements exist in an analysis window, records will be chosen based on the following rules if a single value is needed:

- For baseline, the last nonmissing value with collection date (and time, if available) on or prior to the first dose date (and time) of study drug will be selected, unless specified differently. If there are multiple records with the same time or no time recorded on the same day, the baseline value will be the average of the measurements for continuous data (except for HIV-1 RNA, see below), or the measurement with the lowest severity (eg, normal will be selected over abnormal for safety electrocardiogram [ECG] findings) for categorical data.
- For postbaseline values (ie, data with collection date [and time, if available] after the first dose date [and time] of study drug):
  - The record closest to the nominal day for that visit will be selected with the exception of CD4 cell counts and CD4% in which the latest record will be selected and HIV-1 RNA level (see below).
  - If there are 2 records that are equidistant from the nominal day, the later record will be selected.
  - If there is more than 1 record on the selected day, the average will be taken for continuous data (except for HIV-1 RNA, see below) and the worse severity will be taken for categorical data, unless otherwise specified.
- For baseline HIV-1 RNA, the latest (considering both date and time) record(s) on or prior to the first dose date and time of study drug will be selected. For postbaseline HIV-1 RNA, the latest record(s) on the window will be selected. For both baseline and postbaseline HIV-1 RNA, if both "HIV RNA Taqman 2.0" and "HIV RNA Repeat" (ie, the HIV-1 RNA result obtained from an additional aliquot of the original sample) are available with the same collection time, the results from the "HIV RNA Repeat" will be selected for analysis purposes; otherwise, if there are multiple "HIV RNA Taqman 2.0" records with the same collection time, the geometric mean will be taken for analysis purposes.

## 4. SUBJECT DISPOSITION

# 4.1. Subject Enrollment and Disposition

Key study dates for the first subject screened, first subject enrolled, last subject enrolled, last subject last visit for the primary efficacy endpoint, and last subject last visit for the CSR will be provided.

A summary of subject enrollment will be provided by cohort, treatment group, and total. The number and percentage of subjects enrolled in each country, investigator within a country, and overall will be summarized. For each column, the denominator for the percentage calculation will be the total number of subjects analyzed for that column.

The randomization schedule used for the study will be provided as an appendix to the CSR.

A summary of subject disposition will be provided by cohort, treatment group, and total based on all screened subjects. This summary will present the number of subjects screened, the number of subjects who met all eligibility criteria but were not enrolled with reasons subjects not enrolled, the number of subjects enrolled, the number of subjects in the Safety Analysis Set, and the number of subjects in each of the categories listed below:

# **Subject Disposition on Study Drug by Phase**

- Main Phase (Up to Week 52 visit)
  - Oral lead-in before the first SC injection
    - Completed study drug
    - Prematurely discontinued study drug with reasons (if applicable)
  - After the first SC injection
    - Received Day 1 SC injection
    - Continuing study drug
    - Completed study drug
    - Prematurely discontinued study drug with reasons (if applicable)

- Extension Phase (Post Week 52 visit)
  - Treated in the extension phase
  - Completed study drug
  - Continuing study drug
  - Prematurely discontinued study drug with reasons (if applicable)

## **Subject Disposition throughout the Study**

- Continuing study
- Completed study
- Prematurely discontinued study with reasons (if applicable)

The denominator for the percentage calculation for the main phase categories and for study disposition categories will be the total number of subjects in the Safety Analysis Set corresponding to that column. The denominator for the percentage calculation for the extension phase categories will be the total number of subjects treated in the extension phase corresponding to that column. In addition, a flowchart will be provided to depict subject disposition on study drug.

The following by-subject listings will be provided by subject ID number in ascending order to support the above summary tables:

- Reasons for premature study drug for each phase/period or study discontinuation throughout the study
- Reasons for screen failure (will be provided by screening ID number in ascending order)

## 4.2. Study Drug Administration and Adherence

Study drug administration and study drug dispensing information will be collected in the Study Drug Administration and Study Drug Accountability eCRFs. Number of subjects receiving oral LEN and SC LEN at each protocol specified visit (Day 1, Day 2, Day 8, Day 15, Day 16, and Day 22 for oral LEN and Day 1 SC, Week 26, Week 52, etc. for SC LEN) will be summarized. Number of subjects receiving oral reload before the first SC injection due to missed scheduled oral dosing or due to missed scheduled SC dosing will also be provided.

Study drug administration and dispensing information including lot number and kit ID (if applicable) will be listed.

The adherence to SC LEN will be assessed by adherence to the projected injection interval, which is 26 weeks (182 days) between 2 adjacent injection visits. The number of days from the projected injection visit date will be calculated for each injection visit (excluding the 1st injection visit) as the injection visit date minus the previous injection visit date plus 1 day minus 182 days. The number of days from the projected injection visit date will be classified into the following categories:

- < 14 days</li>
- -14 to -8 days
- -7 to -3 days
- $\pm 2$  days
- 3 to 7 days
- 8 to 14 days
- > 14 days

The number and percentage of subjects in each category will be summarized by cohort and treatment group and overall for the injection visits of interest.

## 4.3. Study Duration

Due to long-acting feature of the study drug, study duration will be calculated for the Functional Monotherapy Period analysis and All LEN analysis, respectively, using the Safety Analysis set.

For the Functional Monotherapy Period analysis, study duration is calculated as the open-label first dose date (defined as the earliest date of either SC LEN or open-label oral LEN) minus first dose date of the blinded study drug plus 1. For subjects who discontinued study drug prior to receiving open-label study drug, last study date will be used to calculate study duration.

For the All LEN analysis, study duration is calculated as the last study date minus the first dose date of LEN plus 1. For subjects who are still on study at the time of the Week 26 analysis, the data cut date will be used to impute the last study day.

Study duration will be expressed in days and will be summarized using descriptive statistics and using the number and percentage of subjects stayed through the following applicable time periods: 1 day, 2 days, 8 days, 15 days, 43 days, 85 days, 127 days, 169 days, 197 days, etc.

#### 4.4. Protocol Deviations

Subjects who did not meet the eligibility criteria for study entry, but enrolled in the study will be summarized. The summary will present the number and percentage of subjects who did not meet at least 1 eligibility criterion and the number of subjects who did not meet specific criteria by cohort, treatment group, and total for the Safety Analysis Set. A by-subject listing will be provided for those subjects who did not meet at least 1 eligibility (inclusion or exclusion) criterion. The listing will present the eligibility criterion (or criteria if more than 1 deviation) that subjects did not meet and related comments, if collected.

Protocol deviations occurring after subjects entered the study are documented during routine monitoring. The number and percentage of subjects with important protocol deviations and number of important protocol deviations by deviation category (eg, eligibility criteria, informed consent) will be summarized by cohort and treatment group for the Safety Analysis Set. A by-subject listing will be provided for those subjects with important protocol deviation.

## 5. BASELINE CHARACTERISTICS

## 5.1. Demographics and Baseline Characteristics

Subject demographic variables (ie, age, sex at birth, gender identity, sexual orientation, race, and ethnicity) and baseline characteristics (body weight [in kg], height [in cm], body mass index [BMI; in kg/m²]) will be summarized by cohort, treatment group, and total using descriptive statistics for continuous variables and using number and percentage of subjects for categorical variables. The summary of demographic data will be provided for the Safety Analysis Set.

For Cohort 1, the Cochran-Mantel-Haenszel (CMH) test will be used to compare the 2 treatment groups (LEN vs. Placebo) for categorical data. The 2-sided Wilcoxon rank sum test will be used to compare the treatment groups (LEN vs. Placebo) for continuous data.

A by-subject demographic and baseline characteristics listing, including the informed consent date, will be provided by subject ID number in ascending order.

#### **5.2.** Other Baseline Characteristics

Other baseline characteristics include disease characteristics, HIV and ARV medication history (prior ARV drugs), failing regimen and resistance, and OBR and resistance at baseline:

Disease characteristics will include the following:

- HIV-1 RNA (log<sub>10</sub> copies/mL)
- HIV-1 RNA categories (copies/mL): (a)  $\leq 100,000$ , (b) > 100,000
- CD4 cell counts (/μL)
- CD4 cell counts categories (/uL): (a) < 50, (b)  $\ge 50$  to < 200, (c)  $\ge 200$  to < 350, (d)  $\ge 350$  to < 500, and (e)  $\ge 500$
- CD4 percentage (%)

HIV and ARV medication history will include the following:

- Number of years since HIV diagnosis
- Number of years since first started HIV treatment
- Number of prior ARV medications (see definition in Section 7.4.1.1 excluding cobicistat [COBI] and ritonavir [RTV] used as a boosting agent)

- Prior ARV medications drug class exposure: (a) nucleoside reverse transcriptase inhibitors (NRTI), (b) non-nucleoside reverse transcriptase inhibitors (NNRTI), (c) protease inhibitor (PI), (d) integrase strand-transfer inhibitor (INSTI), (e) fusion inhibitor (eg, enfuvirtide), (f) CCR5 entry inhibitor (eg, maraviroc), (g) CD4-directed post-attachment inhibitor (eg, ibalizumab), (h) attachment inhibitor (eg, fostemsavir), (i) Other, if applicable
- Number of subjects with known resistance to  $\geq 2$  drugs in class

Failing regimen and resistance will include the following:

- Number of failing regimen (see definition in Section 7.4.1.2 excluding COBI and RTV used as a boosting agent)
- Failing regimen class exposure (a) NRTI, (b) NNRTI, (c) PI, (d) INSTI, (e) fusion inhibitor, (f) CCR5 entry inhibitor, (g) CD4-directed post-attachment inhibitor (eg, ibalizumab), (h) attachment inhibitor (eg, fostemsavir), (i) Other, if applicable
- OSS based on failing regimen
- GSS based on failing regimen
- PSS based on failing regimen

OBR and resistance will include the following:

- Number of ARV medications in the baseline OBR
- Baseline OBR drug class exposure (a) NRTI, (b) NNRTI, (c) PI, (d) INSTI, (e) fusion inhibitor, (f) CCR5 entry inhibitor, (g) CD4-directed post-attachment inhibitor (eg, ibalizumab), (h) attachment inhibitor (eg, fostemsavir), (i) Other, if applicable
- OSS based on baseline OBR (as continuous variable and categorical variable: 0, 0.5, 1, 1.5, 2, > 2);
- GSS based on baseline OBR (as continuous variable and categorical variable: 0, 0.5, 1, 1.5, 2, > 2);
- PSS based on baseline OBR (as continuous variable and categorical variable: 0, 0.5, 1, 1.5, 2, > 2);

Other baseline characteristics will be summarized by cohort and treatment group and overall using descriptive statistics for continuous variables and using number and percentage of subjects for categorical variables. The summary of other baseline characteristics will be provided for the Safety Analysis Set.

For Cohort 1, the CMH test will be used to compare the 2 treatment groups for categorical data and the 2-sided Wilcoxon rank sum test will be used to compare the treatment groups for continuous data.

A by-subject listing of other baseline characteristics will be provided by subject ID number in ascending order.

# **5.3.** Medical History

Medical history will be collected at screening including HIV-1 related disease events. Medical history data will be coded and listed.

## 6. EFFICACY ANALYSES

## 6.1. Primary Efficacy Endpoint

The primary efficacy endpoint is the proportion of subjects in Cohort 1 achieving  $\geq 0.5 \log_{10}$  reduction from baseline in HIV-1 RNA at the end of the Functional Monotherapy Period. Only data collected up to Day 1 SC or Day 15 visit will be included in the primary efficacy analysis. If Day 1 SC or Day 15 visit is missing, only data collected within 15 days from the first dose date of the blinded study drug or up to the first dose date of open-label study drug, whichever is the earliest, will be included. The primary analysis of the efficacy endpoint will be based on the FAS for the Functional Monotherapy Period analysis.

The null hypothesis is that there is no difference in the proportion of subjects achieving  $\geq 0.5 \log_{10}$  reduction from baseline at the end of the Functional Monotherapy Period (between the LEN group and the Placebo group in Cohort 1); the alternative hypothesis is that there is a difference (LEN – Placebo) in the proportion of subjects achieving  $\geq 0.5 \log_{10}$  reduction from baseline at the end of the Functional Monotherapy Period between the 2 treatment groups in Cohort 1. For subjects with missing HIV-1 RNA values at the end of the Functional Monotherapy Period, the value will be imputed using the last observation carried forward method. The difference in proportions between 2 treatment groups will be compared using an unconditional exact method using 2 invert 1-sided tests {Chan 1999} with an alpha level at 0.05 to evaluate superiority. The p-value and 95% confidence interval (CI) for the point estimate of treatment difference in proportions will be estimated and constructed using the Chan and Zhang method carried out by the following SAS codes:

```
proc freq data = example;
table trt*outcome /riskdiff(CL=(exact)) alpha=0.05;
exact barnard RISKDIFF(METHOD=SCORE);
output out=ciexact (keep=_RDIF1_ XL_RDIF1 XU_RDIF1) riskdiff;
run;
```

A secondary analysis of the primary efficacy endpoint based on the PP analysis set for the Functional Monotherapy Period analysis will also be performed to evaluate the robustness of the primary endpoint based on the FAS.

## 6.2. Secondary Efficacy Endpoints

The secondary efficacy endpoints are the proportions of subjects in Cohort 1 with HIV-1 RNA < 50 and < 200 copies/mL at Weeks 26 and 52 using the US FDA-defined snapshot algorithm. Analysis will be based on the FAS for the All LEN analysis. Only results at Week 26 will be included in the Week 26 analysis as the majority of subjects will not have reached Week 52 at that time.

# 6.2.1. US FDA-defined Snapshot Algorithm

The analysis window at Week 26 is defined as from Study Day 184 to Study Day 232, inclusive, where Study Day is calculated from the first dose of oral LEN. All HIV-1 RNA data collected on-treatment (eg, data collected up to 196 days [28 weeks] from the last dose of SC LEN) will be used in the snapshot algorithm. Virologic outcome will be defined as the following categories:

- HIV-1 RNA < 50 copies/mL: this includes subjects who have the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 26 analysis window
- HIV-1 RNA  $\geq$  50 copies/mL: this includes subjects
  - Who have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window, or
  - Who do not have on-treatment HIV-1 RNA data in the Week 26 analysis window and
    - Who discontinue study drug prior to or in the Week 26 analysis window due to lack of efficacy, or
    - Who discontinue study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL
- No Virologic Data in the Week 26 analysis window: this includes subjects who do not have on-treatment HIV-1 RNA data in the Week 26 analysis window because of the following:
  - Discontinuation of study drug prior to or in the Week 26 analysis window due to AE or death (regardless of whether the last available on-treatment HIV-1 RNA < 50 copies/mL or not) or,
  - Discontinuation of study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and the last available on-treatment HIV-1 RNA < 50 copies/mL or,</li>
  - Missing data during the window but on study drug.

The number and percentage of subjects with HIV-1 RNA < 50 copies/mL, HIV-1 RNA ≥ 50 copies/mL, and reasons for no virologic data at Week 26 will be summarized. The 95% CI for the percentage of subjects with HIV-1 RNA < 50 copies/mL will be constructed using the Exact method.

The proportion of subjects in Cohort 1 with HIV-1 RNA < 200 copies/mL at Week 26 will also be summarized in the same manner using the US FDA-defined snapshot algorithm.

The flowchart of the US FDA-defined snapshot algorithm is provided in Section 12 (Appendix 1).

# 6.3. Other Efficacy Endpoints

## 6.3.1. Definition of Other Efficacy Endpoints

Other efficacy endpoints that will be performed for the specified analysis are provided below.

Other Efficacy Endpoints	Functional Monotherapy Period Analysis	ALL LEN Analysis
Proportion of subjects in Cohort 2 with HIV-1 RNA < 50 and < 200 copies/mL at Week 26 using the US FDA-defined snapshot algorithm		X
Change from baseline in HIV-1 RNA (copies/mL) by visit	X	X
Change from baseline in CD4 cell count (/uL) by visit		X
Proportion of subjects with HIV-1 RNA < 50 copies/mL by visit based on Missing = Failure and Missing = Excluded analyses		X

## 6.3.2. Analysis of Other Efficacy Endpoints

Proportion of subjects in Cohort 2 with HIV-1 RNA < 50 and < 200 copies/mL at Week 26 using the US FDA-defined snapshot algorithm will be summarized in the same manner as defined for the secondary efficacy endpoint. Analysis will be based on FAS for the All LEN analysis set for subjects who receive at least 1 dose of SC injection and who have reached Week 26 at the time for the Week 26 analysis.

Baseline and the change from baseline in HIV-1 RNA (log<sub>10</sub> copies/mL) for the Functional Monotherapy analysis will be summarized by treatment groups and visits for Cohort 1 only using descriptive statistics. The differences in changes from baseline in log<sub>10</sub> HIV-1 RNA between the 2 treatment groups and the associated 95% CI will be constructed using analysis of covariance models, including treatment group as fixed effect and baseline log<sub>10</sub> HIV-1 RNA as continuous variable in the model

Baseline and the change from baseline in HIV-1 RNA ( $log_{10}$  copies/mL) and CD4 cell count (/ $\mu$ L) by visit for the all LEN analysis will be summarized using descriptive statistics.

Mean  $\pm$  95% CI of the change from baseline in HIV-1 RNA ( $log_{10}$  copies/mL) will be plotted by visit.

Number and percentage of subjects with HIV-1 RNA < 50 copies/mL by visit will be analyzed using the following analyses:

• Missing = Failure (M = F):

In this approach, missing data will be treated as virologic failure and summarized into the "missing" category (see list of HIV-RNA categories below). The denominator for percentages at a visit is the number of subjects in the FAS, excluding ongoing subjects who have missing HIV-1 RNA at a visit and have not reached the upper limit of the analysis window for the corresponding visit.

• Missing = Excluded (M = E):

In this approach, missing data will be excluded in the computation of the percentages (ie, missing data points will be excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit is the number of subjects in the FAS with nonmissing HIV-1 RNA value at that visit.

No statistical testing is planned. The number and percentage of subjects with HIV-1 RNA in the following categories will be summarized:

- < 50 copies/mL
  - -- < 20 copies/mL
    - < 20 copies/mL Not Detectable
    - < 20 copies/mL Detectable</p>
  - -20 to < 50 copies/mL
- 50 to < 200 copies/mL
- 200 to < 400 copies/mL
- 400 to < 1000 copies/mL
- $\geq 1000 \text{ copies/mL}$
- Missing (only applicable to M = F analysis)

Analysis of the other efficacy endpoints will be based on the FAS.

# 6.4. Subgroup Analysis

Analysis of subgroups (defined in Section 3.4.1) will be performed for the proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 26 as determined by the US FDA-defined snapshot algorithm. Subgroup analysis will be performed on subjects who have reached Week 26 at the time for the Week 26 analysis in the FAS for the All LEN analysis. Results will be descriptive without statistical testing. The 95% CIs of the proportions will be provided using the exact method.

# 6.5. Changes from Protocol-Specified Efficacy Analyses

No change from protocol-specified efficacy analysis is planned.

## 7. SAFETY ANALYSES

#### 7.1. Adverse Events and Deaths

## 7.1.1. Adverse Event Dictionary

Clinical and laboratory AEs will be coded using the current version of the Medical Dictionary for Regulatory Activities (MedDRA). System organ class (SOC), high-level group term, high-level term (HLT), preferred term (PT), and lower-level term will be provided in the AE dataset.

# 7.1.2. Adverse Event Severity

Adverse events are graded by the investigator as Grade 1, 2, 3, 4, or 5 according to toxicity criteria specified in the protocol. The severity grade of events for which the investigator did not record severity will be categorized as "missing" for tabular summaries and data listings. The missing category will be listed last in summary presentation.

## 7.1.3. Relationship of Adverse Events to Study Drug

Related AEs are those for which the investigator selected "Related" on the AE eCRF to the question of "Related to Study Treatment." Relatedness will always represent the investigator's choice, not that of the medical monitor. Events for which the investigator did not record relationship to study drug will be considered related to study drug for summary purposes. However, by-subject data listings will show the relationship as missing.

#### 7.1.4. Serious Adverse Events

Serious adverse events (SAEs) will be identified and captured as SAEs if the AEs met the definitions of SAEs that were specified in the study protocol. SAEs captured and stored in the clinical database will be reconciled with the SAE database from the Global Patient Safety (formerly known as Pharmacovigilance and Epidemiology) before data finalization.

## 7.1.5. Treatment-Emergent Adverse Events

## 7.1.5.1. Definition of Treatment-Emergent Adverse Events

The TEAEs are defined as any AEs that begins on or after the date of first dose of study drug or any AEs leading to premature discontinuation of study drug.

## 7.1.5.2. Incomplete Dates

If the onset date of the AE is incomplete and the AE stop date is not prior to the first dose date of study drug, then the month and year (or year alone if month is not recorded) of onset determine whether an AE is treatment emergent. The event is considered treatment emergent if the AE onset is the same as or after the month and year (or year) of the first dose date of study drug.

An AE with completely missing onset and stop dates, or with the onset date missing and a stop date later than the first dose date of study drug, will be considered to be treatment emergent. In addition, an AE with the onset date missing and incomplete stop date with the same or later month and year (or year alone if month is not recorded) as the first dose date of study drug will be considered treatment emergent.

When calculating the duration of event or time to onset, the following imputation rule will be used:

Missing start month/day: Jan 1/first day of the month will be used unless this is before the start date of study drug; in this case the study drug start date will be used;

Missing stop month/day: Dec 31/last day of the month will be used, unless this is after the last study date; in this case the last study date will be used.

Completely missing start or end dates will remain missing, with no imputation applied.

#### 7.1.6. Summaries of Adverse Events and Deaths

Treatment-emergent AEs will be summarized based on the Safety Analysis Set.

### 7.1.6.1. Summaries of AE Incidence in Combined Severity Grade Subsets

A brief, high-level summary of the number and percentage of subjects who experienced at least 1 TEAE in the categories described below will be provided for the Functional Monotherapy Period analysis and the All LEN analysis. All deaths observed in the study will also be included in this summary.

The number and percentage of subjects who experienced at least 1 TEAE will be provided and summarized by SOC and PT and by PT only, unless specified otherwise, for the following AE categories:

- TEAEs
- TEAEs with Grade 3 or higher
- TEAEs with Grade 2 or higher
- TE treatment-related AEs
- TE treatment-related AEs with Grade 3 or higher
- TE treatment-related AEs with Grade 2 or higher
- TE SAEs
- TE treatment-related SAEs

- TEAEs leading to death (by SOC and PT only)
- TEAEs leading to premature discontinuation of study drug
- TEAEs leading to premature discontinuation of study

Multiple events will be counted only once per subject in each summary. For summaries by SOC and PT, AEs will be summarized and listed first in alphabetic order of SOC and then by PT in descending order of total frequency within each SOC. For summaries by PT, AEs will be summarized and listed by PT in descending order of total frequency. For summaries by severity grade, the most severe grade will be used for those AEs that occurred more than once in an individual subject during the study.

In addition, data listings will be provided for the following:

- All AEs
- All SAEs
- All Deaths
- All AEs with severity of Grade 3 or higher
- All AEs leading to discontinuation of study drug
- All AEs leading to discontinuation of study

For each listing, whether the event is treatment emergent will be indicated.

#### 7.1.7. Additional Analysis of Adverse Events

## 7.1.7.1. Study Drug Related Injection Site Reactions

Additional analysis of AEs will be performed for injection site reaction (ISR) related to study drug, which is defined as an AE related to study drug with HLT of "Injection Site Reactions". The following summaries will be provided for each SC injection visit (eg, Day 1 SC, Week 26) and the overall using the All LEN analysis.

- Number of subjects received SC injection
- Number and percentage of subjects with study drug related ISRs
- Number and percentage of subjects with study drug related ISRs by grade
- Number and percentage of subjects with study drug related ISRs by PT term

The denominator for the percentage calculation for the by visit summary and the overall summary will be based on the total number of subjects who receive at least 1 SC injection at the visit of interest and the total number of subjects who receive at leave 1 SC injection at any injection visit, respectively.

Duration of the ISR will also be calculated and summarized. Duration for a given event is defined as the ISR stop date minus the ISR onset date plus 1 day. For ISR with ongoing stop date, stop date will be imputed as last study date or data cut date, whichever is the earliest. Duration of ISR events in days will be summarized using descriptive statistics.

A by-subject listing for study drug related ISRs and the corresponding duration will be provided.

## 7.2. Laboratory Evaluations

Laboratory data collected during the study will be analyzed and summarized using both quantitative and qualitative methods. Summaries of laboratory data will be provided for the Safety Analysis Set and will include all available data at the time of the database snapshot for the interim analysis. The analysis will be based on values reported in conventional units. When values are below the LOQ, they will be listed as such, and the closest imputed value will be used for the purpose of calculating summary statistics as specified in Section 3.7 Hemolyzed test results will not be included in the analysis, but they will be listed in by-subject laboratory listings.

#### Calcium Corrected for Albumin

Calcium corrected for albumin will be calculated and summarized for the study. The following formula will be used when both serum calcium and albumin results for a given blood drawn are available and serum albumin value is < 4.0 g/dL.

Calcium corrected for albumin (mg/dL) = serum calcium (mg/dL) +  $0.8 \times (4.0 - \text{albumin (g/dL)})$ 

Toxicity grading for calcium will be applied based on the corrected values.

#### **Estimated Glomerular Filtration Rate**

The following formulae will be used to calculate the estimated glomerular filtration rate using Cockcroft-Gault formula (eGFR $_{CG}$ ):

$$eGFR_{CG}$$
 (mL/min) = [(140 - age (yrs)) × weight (kg) × (0.85 if female)] / (SCr (mg/dL) × 72),

where weight is total body mass in kilograms and SCr is serum creatinine.

A by-subject listing for laboratory test results will be provided by subject ID number and visit in chronological order for hematology, (urine) chemistry, and urinalysis separately. Values falling outside of the relevant reference range and/or having a severity grade of 1 or higher based on Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017, will be flagged in the data listings, as appropriate.

No formal statistical testing is planned.

# 7.2.1. Summaries of Numeric Laboratory Results

Descriptive statistics will be provided by treatment group for white blood cells, neutrophils (absolute result and %), lymphocytes (absolute result and %), creatinine, estimated glomerular filtration rate (eGFR) by CG, albumin, alkaline phosphatase, alanine amino transferase (ALT), aspartate amino transferase (AST), and total bilirubin as follows:

- Baseline values
- Values at each postbaseline visit
- Change from baseline at each postbaseline visit

A baseline laboratory value will be defined as the last measurement obtained on or prior to the date of first dose of study drug. Change from baseline to a postbaseline visit will be defined as the visit value minus the baseline value. The mean, median, Q1, Q3, minimum, and maximum values will be displayed to the reported number of digits; SD values will be displayed to the reported number of digits plus 1.

Median (Q1, Q3) of the change from baseline values for the above laboratory tests (except for % neutrophils and lymphocytes) will be plotted using a line plot by cohort and treatment group and visit.

In the case of multiple values in an analysis window, data will be selected for analysis as described in Section 3.8.3.

## 7.2.2. Graded Laboratory Values

The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017, will be used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 includes all values that do not meet the criteria for an abnormality of at least Grade 1. For laboratory tests with criteria for both increased and decreased levels, analyses for each direction (ie, increased, decreased) will be presented separately.

# 7.2.2.1. Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline visit. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed at any postbaseline visit will be considered treatment emergent.

#### 7.2.2.2. Summaries of Laboratory Abnormalities

The summaries (number and percentage of subjects) for treatment-emergent laboratory abnormalities and Grade 3 or 4 laboratory abnormalities will be provided by lab test; subjects will be categorized according to the most severe postbaseline abnormality grade for a given lab test.

Graded laboratory abnormalities will be summarized for the Functional Monotherapy and All LEN analyses. Grade 3 or 4 laboratory abnormality will be summarized for the All LEN analysis only. For all summaries of laboratory abnormalities, the denominator is the number of subjects with nonmissing postbaseline values.

A by-subject listing of treatment-emergent laboratory abnormalities and treatment-emergent Grade 3 or 4 laboratory abnormalities will be provided by subject ID number and visit in chronological order. This listing will include all test results that were collected throughout the study for the lab test of interest, with all applicable severity grades displayed.

### 7.3. Body Weight and Vital Signs

Descriptive statistics will be provided for the All LEN analysis for body weight, BMI, and vital signs as follows:

- Baseline value
- Values at each postbaseline visit
- Change from baseline at each postbaseline visit

A baseline value will be defined as the last available value collected on or prior to the date of first dose of study drug. Change from baseline to a postbaseline visit will be defined as the postbaseline value minus the baseline value.

In the case of multiple values in an analysis window, data will be selected for analysis as described in Section 3.8.3. No formal statistical testing is planned.

A by-subject listing of vital signs will be provided by subject ID number and visit in chronological order. Body weight, height, and BMI will be included in the vital signs listing, if space permits. If not, they will be provided separately.

#### 7.4. Antiretroviral Medications and Concomitant Medications

#### 7.4.1. Antiretroviral Medications

The ARV medications are defined as nonstudy drug ARV medications used prior to, during, or after the study (if collected). The ARV medications are recorded on the ARV eCRF and will be coded using the World Health Organization (WHO) Drug Dictionary for ARV medications. The WHO preferred name and drug code will be attached to the clinical database. All ARV medications recorded on the ARV eCRF will be listed.

#### 7.4.1.1. Prior Antiretroviral Medications

Prior ARV medications are defined as any nonstudy drug ARV medications with a start date prior to the first dose date of study drug regardless of when the stop date is. If a partial start date is entered, the medication will be considered prior unless the month and year (if day is missing) or year (if day and month are missing) of the start date are after the first dose date. Medications with a completely missing start date will be included in the prior medication summary, unless otherwise specified.

Prior ARV medications by indicidual agent will be summarized by drug class and preferred name (based on the WHO coding terms) using the number and percentage of subjects for each cohort and treatment group. A subject reporting the same medication more than once will be counted only once within each drug class when calculating the number and percentage of subjects who received that medication. The summary will be ordered alphabetically by drug class and then by preferred term in descending order of the total frequency. For drugs with the same frequency, sorting will be done alphabetically.

In addition, number of prior ARVs by individual (excluding COBI and RTV used as a boosting agents) and prior ARV drug class exposure will be summarized in the baseline characteristics table mentioned in Section 5.2.

#### 7.4.1.2. Antiretroviral Medications as Failing Regimen

The ARV medications as failing regimen is defined as any nonstudy drug ARV medications that are used on Day -1, the day before the first dose date of study drug. The failing regimen will be summarized in the same manner as the prior ARV medications by drug class and preferred term. In addition, the number of failing regimens by individual agent and failing regimens by drug class (excluding COBI and RTV used as a boosting agents) will be included in the baseline characteristics table mentioned in Section 5.2.

The GSS, PSS, and OSS will be calculated for failing regimen by summing up the available sensitivity/susceptibility scores from all drugs in the failing regimen based on resistance assessments from genotypic (GSS) testing and phenotypic (PSS) testing, and the overall assessments from both tests (OSS). The details of the calculation are available in the programming specification (Appendix 1).

#### 7.4.1.3. Optimized Background Regimen at Baseline

The OBR at baseline is defined as any nonstudy drug ARV medications that were started on or prior to Study Day 28 from the first dose date of open-label LEN and were used for a minimum duration of 28 days on or after the first dose date of open-label LEN. The ARV medications taken on and after the open-label first dose date with temporary interruption will be considered as the same ARV. The earliest start date and the latest end date of the same ARV will be used in the calculation to define baseline OBR. The OBR by individual agent will be summarized in the same manner as the prior ARV medications by drug class and preferred term. The number of OBR by individual agent and OBR by drug class (excluding COBI and RTV used as a boosting agents) will be summarized for the All LEN analysis.

A listing of subjects with OBR change during the study will be provided. The OBR change during the study includes:

- 1) Added new ARV that is not part of the baseline OBR;
- 2) Stopped any ARV that is part of the OBR;
- 3) Any interruption of ARV that is part of the OBR during the study

The listing format will be the same as the listing of non-study drug ARV medication, with only the subjects with OBR change included.

In addition, the number of OBR by individual agent and OBR by drug class (excluding COBI and RTV used as a boosting agents) will be included in the baseline characteristics table mentioned in Section 5.2.

The GSS, PSS, and OSS will be calculated for OBR at baseline by summing up the available sensitivity/susceptibility scores from all drugs in the baseline OBR based on resistance assessments from genotypic (GSS) testing and phenotypic (PSS) testing, and the overall assessments from both tests (OSS). The details of the calculation are available in the programming specification (Appendix 1).

#### 7.4.2. Concomitant Medications

Concomitant medications are defined as non-ARV medications taken on and after first dose date of study drug. Use of concomitant medications will be summarized by preferred name using the number and percentage of subjects and cohort based on the Safety Analysis Set in the All LEN analysis. A subject reporting the same medication more than once will be counted only once when calculating the number and percentage of subjects who received that medication. The summary will be ordered by preferred term in descending order of the overall frequency. For drugs with the same frequency, sorting will be done alphabetically.

For the purposes of analysis, any medications with a start date prior to or on the first dose date of study drug and continued to be taken after the first dose date, or started after the first dose date will be considered concomitant medications. Medications started and stopped on the same day as the first dose date will also be considered concomitant. Medications with a stop date prior to the date of first dose date of study drug will be excluded from the concomitant medication summary. If a partial stop date is entered, any medication with the month and year (if day is missing) or year (if day and month are missing) prior to the date of first study drug administration will be excluded from the concomitant medication summary. If a partial start date is entered, any medication with the month and year (if day is missing) or year (if day and month are missing) after the study drug stop date will be excluded from the concomitant medication summary. Medications with completely missing start and stop dates will be included in the concomitant medication summary, unless otherwise specified.

A by-subject listing for all concomitant medications will be listed.

## 7.5. Electrocardiogram Results

## 7.5.1. Investigator Electrocardiogram Assessment

The investigators' assessment of ECG results (normal; abnormal, not clinically significant; abnormal, clinically significant) are collected at screening only. A by-subject listing for ECG assessment results will be provided by subject ID number.

## 7.6. Other Safety Measures


A data listing will be provided for subjects experiencing pregnancy and subjects using/misusing any substances (eg, illicit drug) during the study, respectively. Physical examination was not collected in the eCRF. Therefore, it will not be included in the analysis.

## 7.7. Subject Subgroup for Safety Endpoints

Incidence of all treatment-emergent AEs will be repeated within each subgroup defined in Section 3.4.2 using the Safety Analysis set for the All LEN analysis. Due to small number of subjects available in each subgroup, results will be descriptive. No formal statistical testing is planned.

## 7.8. Changes from Protocol-Specified Safety Analyses

No change from protocol-specified safety analyses is planned.





## 9. REFERENCES

- Chan IS, Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 1999;55 (4):1202-9.
- Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med 2018;379 (7):645-54.
- U. S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. Guidance for Industry. Silver Spring, MD. November, 2015.

## 10. SOFTWARE

SAS® Software Version 9.4. SAS Institute Inc., Cary, NC, USA.

nQuery Advisor® Version 7.0. Statistical Solutions, Cork, Ireland.

Phoenix WinNonlin® 7.0 Pharsigh Corporation, Princeton, NJ, USA.

## 11. SAP REVISION

Revision Date (DD MMM YYYY)	Section	Summary of Revision	Reason for Revision			

#### **12. APPENDICES**

Schedule of Assessments

Flowchart of US FDA-defined Snapshot Algorithm

Appendix 1. Appendix 2 Appendix 3. **Programming Specifications** 

## **Appendix 1.** Schedule of Assessments

"Subject" was used in the SAP body text and "participant" in the Appendix 2 remained consistent with the Protocol.

	Screeninga	Cohort Selection <sup>b</sup>	Day 1°	Day 2	Day 5	Day 8	Day 15 <sup>d</sup>	Day 16 <sup>d</sup>	Day 19 <sup>d</sup>	Day 22 <sup>d</sup>	Day 1 SC	Weeks 4, 10, 16, 22, 26, 36	Week 52 and visits thereafter <sup>e</sup>	30, 90 and 180 Day Follow-Up <sup>f</sup>	Early Termination <sup>g</sup>
Written Informed Consent/Assent/Parental Consent	X														
Medical History	X														
Demographic Information	X														
Complete Physical Examination	X		X				X				Х	X <sup>h</sup>	$X^{\mathrm{h}}$		X
Symptom Directed Physical Examination				X		X		X		X		X <sup>h</sup>	X <sup>h</sup>	X	
Vital Signs <sup>i</sup> (include weight)	X		X	X		X	X	X		X	X	X	X	X	X
12-lead ECG (supine)	X														
Height	X														
Hematology <sup>i</sup> , Chemistry <sup>k</sup> , Estimated GFR, Urinalysis <sup>l</sup> , Urine Chemistry <sup>l</sup> , CD4+ Cell Count	Х		X			X	X			X	X	X	X	X	X
Urine Storage Sample			X	X		X	X	X		X	X	X	X		X
Serum Pregnancy Test <sup>m</sup>	X														
Serum FSH <sup>n</sup>	X														
Urine Pregnancy Test <sup>m</sup>			X			Х	X			Х	Х	X	X	X	X
HBV, HCV Testing	X														
HIV-1 Genotyping/Phenotyping	X														
Plasma HIV-1 RNA	X	X	X	Х		Х	Х	X		Х	Х	X	X	X	X

	Screening <sup>a</sup>	Cohort Selection <sup>b</sup>	Day 1°	Day 2	Day 5	Day 8	Day 15 <sup>d</sup>	Day 16 <sup>d</sup>	Day 19 <sup>d</sup>	Day 22 <sup>d</sup>	Day 1 SC	Weeks 4, 10, 16, 22, 26, 36	Week 52 and visits thereafter <sup>e</sup>	30, 90 and 180 Day Follow-Up <sup>f</sup>	Early Termination <sup>g</sup>
Plasma Storage Sample	X	X	X	X		X	X	X		X	X	X	X	X	X
CCI															
CCI															
CCI															
Oral GS-6207 Administration <sup>t</sup>			X	X		X	X	X		X					
Begin Optimized Background Regimen <sup>u</sup>			X				X				X				
SC GS-6207 Administration <sup>v</sup>											X	X	X		
Symptoms Distress Module, SF-36, EQ-5D-5L <sup>w</sup>			X									X	X		
Numeric Pain Scale <sup>x</sup>											Х	X	X		
Injection Site Reaction Worksheet <sup>x</sup>											X	X	X		
	T		I					I							

Screening evaluations must be completed within 42 days prior to Day 1.

Χ

b Cohort Selection visit to be completed 14 to 30 days after the Screening visit until Cohort 1 is fully enrolled

Χ

- c Day 1 tests and procedures must be completed prior to study drug administration
- d Day 15, 16, 19 and 22 visits will be completed by Cohort 1B participants only
- e At the Week 52 visit, CCI

Adverse Events/

Concomitant Meds

Participants will receive SC GS-6207 every 6 months (26 weeks) starting at Week 52 visit, while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead Sciences elects to discontinue the study in the country.

Χ

Χ

Χ

X

- f Participants may be required to return to the clinic for a 30, 90 and 180-Day Follow-Up Visit after Early Termination visit as noted in section 6.4.1.
- g Early Termination visit to be completed, if participant decides to discontinue study drug prior to completing Week 52 visit or prior to study completion. Investigators should counsel participant regarding the importance of continuing a complete ARV therapy in accordance to standard of care, and refer participant to an appropriate HIV treatment facility


- i Vital signs blood pressure, pulse, respiration rate, and temperature, weight
- j Hematology: CBC with differential and platelet count
- k Chemistries: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, lipase, magnesium, phosphorus, potassium, sodium, uric acid (except at Cohort Selection, Days 2, 5, 16 and 19 visits)
- Urinalysis and Urine Chemistry: including color & clarity, specific gravity, pH, glucose, ketones, bilirubin, urobilinogen, blood, nitrite, leukocyte esterase and microscopic (if microscopic elements are seen), urine protein, albumin, creatinine, phosphate, calcium, magnesium and uric acid (except at Cohort Selection, Days 2, 5, 16 and 19 visits)
- m All women will have a serum test performed at Screening. Urine pregnancy test will be performed at all subsequent visits for women of child bearing potential (except at Days 2, 5, 16 and 19). Positive urine pregnancy tests will be confirmed with a serum test
- n FSH test is required for women who are < 54 years old and have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure

Complete physical examination to be completed at Weeks 26 and 52, symptom directed physical examination to be completed at all other visits

- During the Maintenance Period, at all visits without SC GS-6207 injections:
- r During the Maintenance Period, at all visits with SC GS-6207 injections:
- t Cohort 1 participants will be administered oral GS-6207 or placebo to match GS-6207 at Days, 1, 2 and 8. Participants who receive placebo to match GS-6207 at Days 1, 2 and 8 will receive oral GS-6207 at Days 15, 16 and 22. Cohort 2 participants will be administered oral GS-6207 at Days 1, 2 and 8
- u Cohort 1 participants will begin an OBR on Day 15 (Cohort 1B) or Day 1 SC (Cohort 1A). Cohort 2 participants will begin an OBR on Day 1. An OBR should be selected based on the screening and/or available historical HIV resistance reports.
- v All participants will be administered SC GS-6207 at Day 1 SC (14 days after the first dose of oral GS-6207) and will continue to receive SC GS-6207 every 6 months (26 weeks). Each SC GS-6207 dosing should occur within 26 and 28 weeks of the previous SC GS-6207 dosing.
- w Participants ≥ 18 years of age at Day 1 visit will complete Symptoms Distress Module, SF-36, EQ-5D-5L at Day 1, Weeks 4, 16, 26 and 52, if available (before completing other study procedures).
- x Participants ≥ 18 years of age at Day 1 visit will complete the Numeric Pain Rating Scale at Day 1 SC, Weeks 26 and 52 (after they receive SC GS-6207 injections)
- y Provide injection site reaction assessment worksheet and instruct the participants to measure and report injection site reactions following the administration of the SC injections

### Appendix 2 Flowchart of US FDA-defined Snapshot Algorithm

The following flowchart for US FDA-defined snapshot algorithm is based on the US FDA Guidance on Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment {U. S. Department of Health and Human Services 2015}



<sup>\*</sup> On-treatment data include all data collected up to 28 weeks (196 days) after the last SC injection date.

## **Appendix 3. Programming Specifications**

- 1) Study drug disposition in Main Phase
  - Oral lead-in before the first SC injection
    - Completed study drug: subjects who received SC LEN injection on Day 1 SC.
    - Continuing study drug: subjects who did not receive SC LEN on Day 1 SC and Study Drug Completion eCRF for the Study Phase = "Treatment" has not been filled out.
    - Prematurely discontinued study drug with reasons: subjects who did not receive SC LEN injection on Day 1 SC and whose Study Drug Completion eCRF for the Study Phase = "Treatment" was marked as "No".
  - After the first SC injection
    - Received Day 1 SC injection.
    - Continuing study drug: subjects who received Day 1 SC injection and Study Drug Completion eCRF for the Study Phase = "Treatment" has not been filled out.
    - Completed study drug: subjects who received Day 1 SC injection and whose Study Drug Completion eCRF for the Study Phase = "Treatment" was marked as "Yes".
    - Prematurely discontinued study drug with reasons: subjects who received Day 1 SC injection and whose Study Drug Completion eCRF for the Study Phase = "Treatment" was marked as "No"
- 2) Number of years since HIV diagnosis is calculated as year of the first dose date minus year of HIV diagnosis. If number of years is great than age, reset number of years = age. Number of years since first started HIV treatment is calculated similarly.
- 3) Further specifications for Functional Monotherapy Period Analysis:
  - a) Efficacy data included for the Functional Monotherapy Period analysis: The "Day 1 SC or Day 15 visit" specified in Section 6.1 of the SAP refers to the visit associated with the first oral lead-in dosing. The Day 1 SC or Day 15 visit associated with oral redosing after subjects have been unblinded will not be included in the Functional Monotherapy Period analysis.
  - b) PP Analysis Set:
    - i) "Added new ARV during the Functional Monotherapy Period" is for ARVs added on or after the date of the first dose of blinded study drug and prior to the Day 1 SC or Day 15 visit date. If Day 1 SC or Day 15 visit date is missing, the date that is 15 days from the date of the first dose of blinded study drug or the date of the first dose of open-label LEN, whichever is earlier, will be used to replace the Day 1 SC and Day 15 visit date in above algorithm.

- ii) "Partial dose" is defined for subjects who receive 1 dose of 300 mg LEN tablet on Day 1 and/or Day 2.
- 4) Drug class and abbreviation of the generic name is tabulated below:

Drug Class	Generic Name	Generic Name Abbreviation		
	Abacavir	ABC		
	Zidovudine	AZT or ZDV		
	Didanosine	ddI		
	Stavudine	d4T		
NRTI	Emtricitabine	FTC		
	Tenofovir alafenamide	TAF		
	Tenofovir Disoproxil Fumarate	TDF		
	Zalcitabine	ddC		
	Lamivudine	3TC		
	Delavirdine	DLV		
	Doravirine	DOR		
NNIDTI	Efavirenz	EFV		
NNRTI	Etravirine	ETR		
	Nevirapine	NVP		
	Rilpivirine	RPV		
	Amprenavir	APV		
	Atazanavir	ATV		
	Darunavir	DRV		
	Indinavir	IDV		
	Fosamprenavir	FPV		
PI	Lopinavir	LPV		
	Nelfinavir	NFV		
	Ritonavir	RTV or /r when used with other PI		
	Saquinavir	SQV		
	Tipranavir	TPV		
	Bictegravir	BIC		
DICTI	Dolutegravir	DTG		
INSTI	Elvitegravir	EVG		
	Raltegravir	RAL		
Fusion Inhibitor	Enfuvirtide	T20		
CCR5 co-receptor Antagonist	Maraviroc	MVC		
CD4-Directed Post Attachment	Ibalizumab	IMAB		
Attachment Inhibitor (AI)	Fostemsavir	FTR		
Pharmacokinetic Enhancers	Cobicistat	COBI or /c when used with PI <sup>2</sup>		
Other	for any ARVs not meeting	g any of above drug classes		

RTV is not considered as an ARV when used as a boosting agent, defined as RTV used as 100 mg QD or BID or as 200 mg QD or BID.

<sup>2.</sup> COBI is not an ARV.

- 5) Study drug administration: Oral reload will be recorded as an "Unscheduled" visit in the Study Drug Administration eCRF. subjects with oral reload prior to the 1st dose of SC have "Unscheduled" dosing visits occurred prior to Day 1 SC visit. Subjects who received a total of 5 tablets of LEN (300 mg) (ie, 2 x 300 mg LEN tablets each for the first 2 days and 1 x 300 mg LEN tablet on the 8th day) prior to "Unscheduled" dosing visits followed by Day 1 SC visit will be classified as oral reload due to missing scheduled SC dosing. Otherwise, subjects will be classified as oral reload due to missing scheduled oral dosing visit.
- 6) GSS, PSS, and OSS calculation for the baseline OBR:

For subjects enrolled based on historical genotypic reports, only GSS data for individual drugs are available, and the OSS is the same as the GSS. For subjects enrolled based on the Screening report, GSS, PSS, and OSS data for individual drugs are provided in the Screening report. On occasions, drug scores for some subjects combined scores from both historical report and Screening report. GSS, PSS, and OSS for the failing regimen and baseline OBR are calculated by summing up the scores from individual drugs in the regimens. GSS, PSS, and OSS data are stored in the Virology Database (GVD, Gilead Virology Database).

#### 7) ARV definitions:

a) Prior ARV: For an ARV with ARV.CMSCAT = "Prior ARV", if the end date of the ARV is missing and not marked as ongoing, the ARV is considered ended prior to the 1st dose date.

#### 8) Injection site reaction:

a) To summarize ISRs by injection visit, each study drug related ISR will be associated with one injection visit (eg, Day 1 SC injection, Week 26 SC Injection, Week 52 SC injection) based on the start date of the ISR. If the start date of the ISR is on or after a given injection visit date and prior to the next injection visit date, if available, the ISR will be associated with that injection visit.

#### b) For ISR summarized by PT:

- i) For the overall summary (ie, subjects received at least one injection), multiple ISRs with the same PT will only be counted once per subject for each PT.
- ii) For by visit summary (ie, subjects received injection for a given injection visit), multiple ISRs associated with the injection visit of interest with the same PT will only be counted once per subject for each PT.

- c) For ISR summarized by grade:
  - i) For the overall summary (ie, subjects received at least one injection), the most severe grade based on all ISRs will be used.
  - ii) For by visit summary (subjects received injection for a given injection visit), the most severe grade from all ISRs associated with the injection visit of interest will be used.

# GS-US-200-4625-Week 26-SAP ELECTRONIC SIGNATURES

Signed by	Meaning of Signature	Server Date (dd-MMM- yyyy hh:mm:ss)
PPD	Clinical Pharmacology eSigned	20-Apr-2021 02:41:45
PPD	Biostatistics eSigned	20-Apr-2021 03:19:27
PPD	Clinical Research eSigned	20-Apr-2021 06:31:39